Category: 2022

VIDEO: Femasys KOL Event

‘Storm Of Change’ Could Propel Industry On Making Daily Oral Contraceptive Available OTC In US

U.S. abortion ruling ignites retail interest in women contraceptive makers

With Roe overturned, Femasys’ permanent contraception has increased appeal

With Roe v. Wade In Rearview, What’s Next For Women’s Health?

What Is TFMR? Termination of Pregnancy for Medical Reasons

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

CEO & Founder of Femasys, Kathy Lee-Sepsick, on Leading in Women’s Health Tech for 18 Years

Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer